Results 191 to 200 of about 103,365 (348)

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]

OTO Open
Sciscent BY, Eberly HW, Lorenz FJ, Goldrich D, Goyal N, Goldenberg D.   +5 more
europepmc   +1 more source

Review for "Cardiovascular Outcomes Trials with Glucagon‐like Peptide‐1 Receptor Agonists: A Comparison of Study Designs, Populations, and Results"

, 2020

openalex   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]

Diabetes Obes Metab
Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Hegedüs L.   +8 more
europepmc   +1 more source

Review for "Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis"

, 2019

openalex   +1 more source

Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists [PDF]

, 2019
Dimitrios Patoulias, Maria‐Styliani Kalogirou, Konstantinos Stavropoulos, Κonstantinos Imprialos, Michael Doumas   +4 more
openalex   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis. [PDF]

Cureus
Nashwan AJ.
europepmc   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review. [PDF]

Ther Adv Psychopharmacol
Lee S, Yin L, Teopiz KM, Wong S, Han Le G, Xiao N, Stahl S, Valentino K, Ho R, Zhang MC, Greg Rhee T, McIntyre RS.   +11 more
europepmc   +1 more source